Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Swapan Chowdhury"'
Autor:
Jayaprakasam Bolleddula, Xiaofei Zhou, Douglas V. Faller, Yuexian Li, Swapan Chowdhury, Dan Zhao, Hélène M. Faessel, Farhad Sedarati, Karthik Venkatakrishnan, Zsuzsanna Papai
Publikováno v:
Investigational New Drugs. 39:488-498
SummaryPevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the results
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f10edb2e4e45379985451ac370d03a6
https://doi.org/10.1007/s10637-020-01017-x
https://doi.org/10.1007/s10637-020-01017-x
Autor:
Afrand Kamali, Mohammad Shadid, Michael D. Smith, Jayaprakasam Bolleddula, Abhi Shah, Swapan Chowdhury
Publikováno v:
Drug Metabolism and Disposition. 48:1239-1245
TAK-164 is an antibody-drug conjugate (ADC) comprising human anti-guanylyl cyclase C (GCC) monoclonal antibody conjugated to indolinobenzodiazepine DNA alkylator IGN-P1 through a cleavable alanine-alanine dipeptide linker. TAK-164 is currently being
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73c7b913bf7e365f1149b6e3dd3ec173
https://doi.org/10.1124/dmd.120.000194
https://doi.org/10.1124/dmd.120.000194
Autor:
Suguru Kato, Swapan Chowdhury, Jayaprakasam Bolleddula, Mihaela Plesescu, Yoshinari Miyata, Abhi Shah, Xiaochun Zhu
Publikováno v:
Drug Metabolism and Disposition. 48:934-943
The PXB-mouse is potentially a useful in vivo model to predict human hepatic metabolism and clearance. Four model compounds, [14C]desloratadine, [3H]mianserin, cyproheptadine, and [3H]carbazeran, all reported with disproportionate human metabolites,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ced06eca08636d58fdba47f17d4f460
https://doi.org/10.1124/dmd.120.000128
https://doi.org/10.1124/dmd.120.000128
Autor:
Cindy Q. Xia, Sandeepraj Pusalkar, Yuexian Li, Karthik Venkatakrishnan, Suresh K. Balani, Lawrence Cohen, Xiaofei Zhou, Wen Chyi Shyu, Jun Johnny Yang, Swapan Chowdhury, Chuang Lu
Publikováno v:
Drug Metabolism and Disposition. 48:217-229
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted as part of a broa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::166eb285f2919cd372a7ec5c53356ca7
https://doi.org/10.1124/dmd.119.087338
https://doi.org/10.1124/dmd.119.087338
Autor:
P. P. Chothe, E. van de Steeg, Catherijne A. J. Knibbe, Ian P.J. Alwayn, Swapan Chowdhury, Andy Z. X. Zhu, L. J. Stevens, Joanne M. Donkers, Wouter H. J. Vaes
Publikováno v:
Drug Metabolism and Disposition, 49(9), 780-789. AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
There is a lack of translational preclinical models that can predict hepatic handling of drugs. In this study, we aimed to evaluate the applicability of normothermic machine perfusion (NMP) of porcine livers as a novel ex vivo model to predict hepati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79e1d07819595c8930b13ced62ae3d42
https://pubmed.ncbi.nlm.nih.gov/34330719
https://pubmed.ncbi.nlm.nih.gov/34330719
Autor:
Xiaofei, Zhou, Farhad, Sedarati, Douglas V, Faller, Dan, Zhao, Hélène M, Faessel, Swapan, Chowdhury, Jayaprakasam, Bolleddula, Yuexian, Li, Karthik, Venkatakrishnan, Zsuzsanna, Papai
Publikováno v:
Investigational New Drugs
Summary Pevonedistat (TAK-924/MLN4924) is an investigational small-molecule inhibitor of the NEDD8-activating enzyme that has demonstrated preclinical and clinical activity across solid tumors and hematological malignancies. Here we report the result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::065441bf123731f5669b7fea7c655324
https://pubmed.ncbi.nlm.nih.gov/33089874
https://pubmed.ncbi.nlm.nih.gov/33089874
Autor:
Sandeepraj Pusalkar, Xiaofei Zhou, Yuexian Li, Shawn Searle, Claudio Dansky Ullmann, Swapan Chowdhury, Karthik Venkatakrishnan
Publikováno v:
Investigational New Drugs. 37:666-673
Aims This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics and safety of the investigational aurora A kinase inhibitor, alisertib, in three patients with advanced malignancies. Methods Part A; patients received a single
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1366b260b3242676acbfbd3bf604ec4c
https://doi.org/10.1007/s10637-018-0693-7
https://doi.org/10.1007/s10637-018-0693-7
Autor:
Michael J. Hanley, Cindy Q. Xia, Swapan Chowdhury, Karthik Venkatakrishnan, Sandeepraj Pusalkar, Mihaela Plesescu, Xiaoquan Zhang, Neeraj Gupta, Jing-Tao Wu
Publikováno v:
Cancer Chemotherapy and Pharmacology. 82:803-814
This metabolite profiling and identification analysis (part of a phase I absorption, distribution, metabolism, and excretion study) aimed to define biotransformation pathways and evaluate associated inter-individual variability in four patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::83cd8661aaa3fe7553c4d003a0f34d61
https://doi.org/10.1007/s00280-018-3671-z
https://doi.org/10.1007/s00280-018-3671-z
Autor:
Cornelis E. C. A. Hop, Swapan Chowdhury, Douglas K. Spracklin, Simone Schadt, Christoph Funk, W. Griffith Humphreys, Angus N. R. Nedderman, Fumihiko Igarashi, Josh Yuan, Chandra Prakash, Frank Runge, Holger Scheible, Mark Kagan, S. Cyrus Khojasteh, Piet Swart, R. Scott Obach, Bojan Bister, Alexander David James, Susanna Tse
Publikováno v:
BASE-Bielefeld Academic Search Engine
Since the introduction of metabolites in safety testing (MIST) guidance by the Food and Drug Administration in 2008, major changes have occurred in the experimental methods for the identification and quantification of metabolites, ways to evaluate co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c0739606a23742034a3be6254e08fa
https://doi.org/10.1124/dmd.117.079848
https://doi.org/10.1124/dmd.117.079848
Autor:
Karthik Venkatakrishnan, Michael J. Hanley, Sandeepraj Pusalkar, Neeraj Gupta, Steven Zhang, Mihaela Plesescu, Xiaoquan Zhang, Bingxia Wang, Dale R. Shepard, Swapan Chowdhury, Cindy Q. Xia
Publikováno v:
Investigational New Drugs. 36:407-415
Summary This two-part, phase I study evaluated the mass balance, excretion, pharmacokinetics (PK), and safety of ixazomib in patients with advanced solid tumors. In Part A of the study, patients received a single 4.1 mg oral solution dose of [14C]-ix
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f8e12a5907ce192f618e42bef8eb5de
https://doi.org/10.1007/s10637-017-0509-1
https://doi.org/10.1007/s10637-017-0509-1